New hope for older AML patients: triple drug combo aims to control disease and prevent relapse
NCT ID NCT04687761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control the disease and then prevent relapse with ongoing maintenance treatment. Participants received up to 4 cycles of treatment, and those who responded could continue maintenance therapy until the disease worsened or side effects became unacceptable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE MORE 60YR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clinico Universitario Virgen de La Arrixaca
Murcia, Spain
-
Hospital Clínic
Barcelona, Spain
-
Hospital San Pedro de Alcántara
Cáceres, Spain
-
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Spain
-
Hospital Universitari Mutua de Terrassa
Terrassa, Spain
-
Hospital Universitari Son Espases
Palma de Mallorca, Spain
-
Hospital Universitario Infanta Leonor
Madrid, Spain
-
Hospital Universitario La Zarzuela
Madrid, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Spain
-
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, Spain
-
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Spain
-
Hospital Universitario de Jerez de La Frontera
Jerez de la Frontera, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, Spain
-
Hospital de León (Complejo Asistencial Universitario de León)
León, Spain
-
Hospital de Sant Joan de Deu (Manresa)
Manresa, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a fourth drug tip the scales against an aggressive leukemia?
- Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
- New drug combination targets rare childhood leukemia that resists standard treatment
- New combo aims to boost survival in older AML patients
- New combo therapy for AML enters early human testing
- Mold infection risk in kids with leukemia: a 14-year review